Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).

Nadia Harbeck,Seock-Ah Im,Carlos H. Barrios,Hervé Bonnefoi,Julie Gralow,Masakazu Toi,Paul Anthony Ellis,Luca Gianni,Sandra M. Swain,Young-Hyuck Im,Michelino De Laurentiis,Zbigniew I. Nowecki,Jigna Shah,Thomas Boulet,Haiying Liu,Harrison Macharia,Peter Trask,Chunyan Song,Eric P. Winer,Ian E. Krop

Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).

2020

500Background: The standard of care for HER2-positive EBC is chemotherapy plus one year of HER2-directed therapy. However, recurrence—particularly in high-risk populations—remains a problem, as doe...

Keywords:

Taxane
Internal medicine
Oncology
Pertuzumab
early breast cancer
Trastuzumab
Trastuzumab emtansine
Medicine
Adjuvant therapy
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations